SCHEMBL3266253

SCHEMBL3266253

NC(=O)COC(=O)NCCC1CCN(c2ccnc3ccccc23)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT2 Q8IXJ6 3/20 0.48
SIRT1 Q96EB6 3/20 0.48
SIRT3 Q9NTG7 3/20 0.48
F10 P00742 2/20 0.45
DRD2 P14416 6/20 0.45
DRD3 P35462 6/20 0.45
ADRB2 P07550 1/20 0.44
NCF1 P14598 1/20 0.44
HTR2A P28223 3/20 0.42
HTR1A P08908 2/20 0.42
DRD4 P21917 2/20 0.42
HTR2C P28335 2/20 0.42
HTR2B P41595 2/20 0.42
PDGFRB P09619 1/20 0.41
AKT1 P31749 1/20 0.40
DRD1 P21728 1/20 0.40
KCNH2 Q12809 1/20 0.40
IDO1 P14902 1/20 0.40
ACACB O00763 1/20 0.38
ACACA Q13085 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3265695 0.89 SIRT2 (0.45) SIRT2SIRT1SIRT3F10DRD2
SCHEMBL1729014 0.84 DRD2 (0.52) SIRT2SIRT1SIRT3F10DRD2
SCHEMBL3270079 0.83 SIRT2 (0.49) SIRT2SIRT1SIRT3DRD2DRD4
SCHEMBL3265727 0.80 HCAR2 (0.45) ACACBACACA
SCHEMBL3270238 0.79 CHRM4 (0.51) SIRT2SIRT1SIRT3DRD2DRD3
SCHEMBL240267 0.78 PDE10A (0.44) DRD2DRD3HTR1AHTR2CKCNH2
SCHEMBL3265698 0.78 CHRM4 (0.48) SIRT2SIRT1SIRT3
SCHEMBL3269252 0.77 DRD2 (0.50) SIRT2SIRT1SIRT3DRD2DRD3
SCHEMBL3266162 0.77 TP53 (0.49)
SCHEMBL3270585 0.77 NPC1 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES SANOFI-AVENTIS (FR) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004207-A1 THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 SIRT2 268/4885SIRT1 987/4885SIRT3 258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.